Alexis Boaz is an Associate in the Health Care and Life Sciences practice, in the Washington, DC, office of Epstein Becker Green. She will be focusing her practice on fraud and abuse, transactional, regulatory, and compliance matters.
Ms. Boaz received her Juris Doctor from The George Washington University Law School (“GW”), where she was a student attorney for the Health Insurance Counseling Project and a recipient of the President’s Volunteer Service Award and GW Excellence in Service Award in recognition of her pro bono work. She also earned a Master of Public Health in Health Policy from The George Washington University – Milken Institute School of Public Health.
During law school, Ms. Boaz interned at various divisions of the U.S. Department of Health and Human Services (“HHS”), including the Office of General Counsel’s Public Health Division and Centers for Medicare & Medicaid Services Division and the Office of Global Affairs’ Division for Trade and Health. She also served as a Health Policy Law Clerk for the U.S. Senate Committee on Finance; as a Health Policy Intern for a public policy think-tank; as a Health Policy Fellow for the Congressional Black Caucus Foundation Health Braintrust; and as a Legal Intern at the White House (in the Executive Office of the President).
Before attending law school, Ms. Boaz earned a Bachelor of Science in Health Care Management and Policy from Georgetown University’s School of Nursing & Health Studies. She also participated in health care-related internships at the HHS Office of Inspector General’s Office of Evaluations and Inspections; the U.S. Senate Committee on Health, Education, Labor & Pensions; a nonprofit, academic health system in Tennessee; the DC Department of Health’s HIV/AIDS, Hepatitis, STD, and TB Administration (“HAHSTA”); an academic teaching hospital in DC; and a national nonprofit public health charitable organization focused on fetal alcohol syndrome.
More Legal and Business Bylines From Alexis Boaz
- Advancing Interoperability and Improving Prior Authorization: No One Said It Would Be Easy! - (Posted On Tuesday, April 02, 2024)
- Last Call for Comments on the Bipartisan Discussion Draft of the SUSTAIN Act: Shaping 340B for the Future - (Posted On Tuesday, March 26, 2024)
- CMS Seeks Stakeholder Feedback About Medicare Transaction Facilitator Services for the Medicare Drug Price Negotiation Program by November 13: Inflation Reduction Act Updates - (Posted On Friday, October 27, 2023)
- State Regulation of Pharmacy Benefit Managers: Tenth Circuit Holds That ERISA and Medicare Part D Preempt Key Parts of Oklahoma PBM Law - (Posted On Tuesday, September 05, 2023)
- CMS Names Its First Ten Negotiated Part D Drugs: Inflation Reduction Act Updates - (Posted On Friday, September 01, 2023)
- Texas Federal Court Issues Fourth Ruling Invalidating Parts of the Administration’s No Surprises Act Regulations - (Posted On Wednesday, August 30, 2023)
- Independent Dispute Resolution Process Halted Following the Government’s Third Major No Surprises Act-Related Loss in Federal Court - (Posted On Monday, August 14, 2023)
- Take Two: CMS’s Second Attempt to Streamline Breakthrough Device Coverage Limited to 5 Devices Per Year - (Posted On Friday, July 21, 2023)
- More Federal Action in the Pharmaceutical Sector as PBM Bill Advances in the Senate - (Posted On Tuesday, May 23, 2023)
- CMS Forwards Its Health Equity Agenda through Its Annual Prospective Payment System Rulemaking Process - (Posted On Tuesday, May 02, 2023)